Revvity (RVTY) Competitors

Revvity presently has a consensus price target of $107.73, indicating a potential upside of 8.06%. Bio-Techne has a consensus price target of $66.77, indicating a potential upside of 40.03%. Given Bio-Techne's stronger consensus rating and higher possible upside, analysts clearly believe Bio-Techne is more favorable than Revvity.

Bio-Techne has a net margin of 9.05% compared to Revvity's net margin of 8.26%. Bio-Techne's return on equity of 13.57% beat Revvity's return on equity.

In the previous week, Bio-Techne had 14 more articles in the media than Revvity. MarketBeat recorded 30 mentions for Bio-Techne and 16 mentions for Revvity. Revvity's average media sentiment score of 0.49 beat Bio-Techne's score of 0.00 indicating that Revvity is being referred to more favorably in the media.

86.7% of Revvity shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 0.9% of Revvity shares are owned by company insiders. Comparatively, 1.3% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Revvity has higher revenue and earnings than Bio-Techne. Revvity is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.3%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.7%. Revvity pays out 13.4% of its earnings in the form of a dividend. Bio-Techne pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Revvity has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

86.7% of Revvity shares are owned by institutional investors. 0.9% of Revvity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Revvity presently has a consensus price target of $107.73, indicating a potential upside of 8.06%. Agilent Technologies has a consensus price target of $163.71, indicating a potential upside of 44.21%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Agilent Technologies is more favorable than Revvity.

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.3%. Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.9%. Revvity pays out 13.4% of its earnings in the form of a dividend. Agilent Technologies pays out 22.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Revvity had 6 more articles in the media than Agilent Technologies. MarketBeat recorded 16 mentions for Revvity and 10 mentions for Agilent Technologies. Agilent Technologies' average media sentiment score of 0.94 beat Revvity's score of 0.49 indicating that Agilent Technologies is being referred to more favorably in the news media.

Agilent Technologies has a net margin of 18.26% compared to Revvity's net margin of 8.26%. Agilent Technologies' return on equity of 24.49% beat Revvity's return on equity.

Revvity has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

Agilent Technologies has higher revenue and earnings than Revvity. Agilent Technologies is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

86.7% of Revvity shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 0.9% of Revvity shares are owned by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Revvity presently has a consensus price target of $107.73, indicating a potential upside of 8.06%. Bio-Rad Laboratories has a consensus price target of $333.00, indicating a potential upside of 36.74%. Given Bio-Rad Laboratories' higher probable upside, analysts clearly believe Bio-Rad Laboratories is more favorable than Revvity.

In the previous week, Revvity had 15 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 16 mentions for Revvity and 1 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 1.13 beat Revvity's score of 0.49 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.

Revvity has a net margin of 8.26% compared to Bio-Rad Laboratories' net margin of 6.52%. Revvity's return on equity of 8.00% beat Bio-Rad Laboratories' return on equity.

Revvity has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

Bio-Rad Laboratories has lower revenue, but higher earnings than Revvity. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

86.7% of Revvity shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 0.9% of Revvity shares are owned by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Revvity presently has a consensus price target of $107.73, indicating a potential upside of 8.06%. Charles River Laboratories International has a consensus price target of $205.86, indicating a potential upside of 20.63%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, analysts clearly believe Charles River Laboratories International is more favorable than Revvity.

In the previous week, Revvity and Revvity both had 16 articles in the media. Charles River Laboratories International's average media sentiment score of 0.61 beat Revvity's score of 0.49 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Revvity has a net margin of 8.26% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Revvity's return on equity.

Revvity has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market.

Revvity has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.